
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
PRNewsWire
Published: Jul 18, 2026, 11:00 AM GMT+9
Sentiment Analysis
Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NasdaqGS: ERAS) of a class action securities lawsuit.
The lawsuit seeks to recover losses on behalf of investors of Erasca, Inc. who were adversely affected if they purchased the Company's shares between January 14, 2025 and April 26, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of California.
Erasca investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-eras/?prs=prn to learn more.
According to the Complaint, Erasca and certain of its executives are charged with failing to disclose material information during the class period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the preclinical data for the Company's ERAS-0015 product, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors, was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (ii) based on the foregoing, the defendants lacked a reasonable basis for their positive statements related to ERAS-0015.
The case is Cheng v. Erasca, Inc., No. 26-cv-03481.
If you invested in Erasca and suffered a loss during the relevant time frame, you have until August 10, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
Source: PRNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.